연구성과로 돌아가기

2021 연구자 정보 (38 / 1146)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 교신저자 여부 Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Heo, Mi Hwa
(Heo, MH)
Keimyung Univ, Dept Internal Med, Div Hematooncol, Dongsan Hosp, Daegu, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Hotko, Yevhen
(Hotko, Y)
F-9068-2019
Hotko, Yevhen
0000-0002-4533-4210
Hotko, Yevhen
[JCR상위 2.2] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane. SCIE 2.2 ONCOLOGY
Jang, You Jin
(Jang, YJ)
Korea Univ, Dept Surg, Guro Hosp, Seoul, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Jung, Mi Ran
(Jung, MR)
Chonnam Natl Univ, Dept Surg, Med Sch, Hwasun, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Kim, Beom Su
(Kim, BS)
Univ Ulsan, Asan Med Ctr, Dept Surg, Seoul, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Kim, Gyunji
(Kim, G)
Sanofi Korea, Seoul, South Korea ABD-7016-2020
Kim, Yuriy

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Kim, Hark Kyun
(Kim, HK)
Natl Canc Ctr, Ctr Gastr Canc, Res Inst & Hosp, Grad Sch Canc Sci & Policy, Goyang, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Kim, Hyun Ki
(Kim, HK)
Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea
0000-0003-2292-5584
Kim, Hyunki
[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Kim, Sohyun
(Kim, S)


[JCR상위 2.2] Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial. SCIE 2.2 ONCOLOGY
Kook, Myeong-Cherl
(Kook, MC)
Natl Canc Ctr, Ctr Gastr Canc, Res Inst & Hosp, Grad Sch Canc Sci & Policy, Goyang, South Korea B-7001-2014
Kook, Moochang
0000-0002-3435-3301
Kook, Myeong-Cherl
[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Kumar, Akshi
(Kumar, A)
Delhi Technol Univ, New Delhi, India Y-9314-2019
Kumar, Akshi
0000-0003-4263-7168
Kumar, Akshi
[JCR상위 2.2] Social, mobile, analytic and cloud technologies: Intelligent Computing for future smart cities SCIE 2.2 CONSTRUCTION & BUILDING TECHNOLOGY;ENERGY & FUELS;GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY anandnayyar@duytan.edu.vn;sara.paiva@estg.ipvc.pt;Paul.editor@gmail.com;akshikumar@dce.ac.in;
Lee, Jong Seok
(Lee, JS)
Univ Ulsan, Asan Med Ctr, Dept Radiol, Coll Med, Seoul, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
Lee, Keun Wook
(Lee, KW)
JQV-8143-2023
Lee, Juhyung

[JCR상위 2.2] Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16). SCIE 2.2 ONCOLOGY
Lee, Kyung-ha
(Lee, KH)


[JCR상위 2.2] Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial. SCIE 2.2 ONCOLOGY
Lee, Nam Su
(Lee, NS)
Soon Chun Hyang Univ Hosp, Dept Internal Med, Seoul, South Korea

[JCR상위 2.2] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer SCIE 2.2 ONCOLOGY ykkang@amc.seoul.kr;
페이지 이동: